日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma

EGFRvIII 的表达及其与野生型 EGFR 的共表达,或推定的癌症干细胞生物标志物 CD44 或 EpCAM 与肝细胞癌患者的预后较差相关

Ozlem Sherif, Said A Khelwatty, Izhar Bagwan, Alan M Seddon, Angus Dalgleish, Satvinder Mudan, Helmout Modjtahedi

Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells

Neratinib 与 Palbociclib 或 Miransertib 联合治疗脑癌细胞的协同作用

Ermira Mulliqi, Said Khelwatty, Anna Morgan, Keyoumars Ashkan, Helmout Modjtahedi

The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells

阿法替尼与达沙替尼或 Miransertib 联合使用可协同抑制胃癌细胞生长

Tina Al-Janaby, Narmin Nahi, Alan Seddon, Izhar Bagwan, Said Khelwatty, Helmout Modjtahedi

Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients

酪氨酸磷酸酶受体γ对慢性粒细胞白血病患者酪氨酸激酶抑制剂治疗反应的预测价值

Mohamed A Ismail, Marzia Vezzalini, Hisham Morsi, Ahmad Abujaber, Ali Al Sayab, Kodappully Siveen, Mohamed A Yassin, Maria Monne, Muthanna Samara, Richard Cook, Claudio Sorio, Helmout Modjtahedi, Nader I Al-Dewik2

Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

单克隆抗体在胰腺癌治疗中的应用:进展、挑战和未来机遇

Gustavo A Arias-Pinilla, Helmout Modjtahedi

Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer

两种新型抗胰腺癌高表达 CD26 和整合素 α3 单克隆抗体的开发及应用

Gustavo A Arias-Pinilla, Angus G Dalgleish, Satvinder Mudan, Izhar Bagwan, Anthony J Walker, Helmout Modjtahedi

Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer

针对一组胰腺癌细胞系中的生长因子受体、CDK 和下游信号分子的药物的协同活性以及拮抗组合的鉴定:对胰腺癌未来临床试验的意义

Tanzeel Khan, Alan M Seddon, Angus G Dalgleish, Said Khelwatty, Nikolaos Ioannou, Satvinder Mudan, Helmout Modjtahedi

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer

假定 CSC 标志物 CD44、CD133、野生型 EGFR 和 EGFRvIII 在转移性结直肠癌中的共表达及预后意义

Said Abdullah Khelwatty, Sharadah Essapen, Izhar Bagwan, Margaret Green, Alan M Seddon, Helmout Modjtahedi

Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer

针对人类胰腺癌中过表达的 CD109 的新型单克隆抗体的开发

Gustavo A Arias-Pinilla, Angus G Dalgleish, Satvinder Mudan, Izhar Bagwan, Anthony J Walker, Helmout Modjtahedi

Inhibitory Effects of Culinary Herbs and Spices on the Growth of HCA-7 Colorectal Cancer Cells and Their COX-2 Expression

烹饪香草和香料对HCA-7结肠直肠癌细胞生长及其COX-2表达的抑制作用

Andrius Jaksevicius, Mark Carew, Calli Mistry, Helmout Modjtahedi, Elizabeth I Opara